BI Asset Management Fondsmaeglerselskab A S Sells 2,968 Shares of Regeneron Pharmaceuticals, Inc. $REGN

BI Asset Management Fondsmaeglerselskab A S reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 47.8% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,239 shares of the biopharmaceutical company’s stock after selling 2,968 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Regeneron Pharmaceuticals were worth $2,503,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $226,000. Arrowstreet Capital Limited Partnership bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $3,183,000. Gabelli Funds LLC raised its holdings in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after purchasing an additional 55 shares during the last quarter. Finally, Sei Investments Co. lifted its position in Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after purchasing an additional 5,120 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Up 0.9%

REGN opened at $618.03 on Wednesday. The firm’s fifty day moving average is $671.09 and its two-hundred day moving average is $730.51. The firm has a market cap of $65.34 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a twelve month low of $514.79 and a twelve month high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.22 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on REGN shares. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Canaccord Genuity Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Leerink Partners reiterated a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Guggenheim increased their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.